Quantcast
Last updated on April 18, 2014 at 7:13 EDT

Latest acute chest syndrome Stories

2013-10-02 13:17:41

Acute chest syndrome (ACS) is a complication of sickle cell disease that is characterized by sudden pain and difficulty breathing. Sickle cell disease can also cause red blood cells to suddenly breakdown and release their contents, which may trigger the onset of ACS. In this issue of the Journal of Clinical Investigation, Solomon Fiifi Ofori-Acquah and colleagues at Emory University asked if hemin, a product released by red blood cells during lysis, triggers ACS in a mouse model of sickle...

2013-01-30 08:29:43

SAN DIEGO, Jan. 30, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated patient recruitment in its pivotal phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease. Santosh Vetticaden, Chief Medical Officer, said: "The substantial effort that went into the design of this study is reflected by the enthusiasm that we have heard from thought leaders and clinical sites who wish to participate. In particular, the...

2011-05-02 19:17:35

This guideline is the first 1 of a series of documents focused on sickle cell disease ENERCA is a European Network for Rare and Congenital Anaemias funded by the European Commission and coordinated by IDIBAPS - Hospital Clínic of Barcelona. Its main purpose is offering an improved public health service to medical practitioners and patients in every aspect of rare anaemias. Recently this year this network published in the American Journal of Hematology (AJH) a series of...

2011-02-14 04:00:00

SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has entered into a definitive agreement to acquire SynthRx, Inc. (SynthRx), a private biotechnology company developing a purified form of a rheologic and antithrombotic agent, poloxamer 188 (188). "The acquisition of SynthRx will be a transformative event for ADVENTRX, adding another late-stage asset to our pipeline," stated Brian M. Culley, Chief Executive Officer of...

2009-03-24 06:00:00

HAYWARD, Calif., March 24 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data from the first cohort of 30 patients, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera's Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue...

2006-06-16 22:30:38

NEW YORK (Reuters Health) - Ninety percent of adults with sickle cell anemia have abnormal lung function tests, according to a report in the American Journal of Respiratory and Critical Care Medicine. Sickle cell anemia is a hereditary disease in which red blood cells assume a sickle shape when body oxygen levels run low. This sets up a vicious circle, because the sickle cells do not efficiently deliver oxygen, leading to the formation of more sickle cells. Severe pain and...